Billionaire hedge fund managers’ stock picks can offer valuable insights for investors. Despite information delays due to SEC reporting requirements, common holdings among top managers can indicate promising investment opportunities.

Taiwan Semiconductor Manufacturing (NYSE: TSM) is a popular choice among billionaires like Chase Coleman, Steve Mandel, David Tepper, and Daniel Loeb. With its crucial role in the AI industry and strong growth potential, TSMC is set to thrive in the coming years.

As global data center expenditures are projected to skyrocket, chip providers like TSMC are poised for significant growth. With a reasonable valuation and strong market position, Taiwan Semiconductor remains an attractive investment option for 2026.

Investors should consider following the lead of top billionaires and investing in Taiwan Semiconductor. The company’s strategic position and anticipated market growth make it a compelling opportunity for substantial returns in the future.

While Taiwan Semiconductor Manufacturing is not on the current top 10 stocks list, it remains a strong contender for investors looking for long-term growth potential. Consider the success stories of past Stock Advisor recommendations and explore the latest investment opportunities with expert guidance. 1. The stock market reached new highs today, with the S&P 500 and Dow Jones Industrial Average both closing at record levels. The S&P 500 rose 0.4% to 3,722.48, while the Dow climbed 0.4% to 30,829.40.

2. In other news, the unemployment rate fell to 6.7% in December, as employers added 140,000 jobs. This marks the smallest increase in employment since the recovery began in May. The leisure and hospitality sector saw the biggest losses, shedding 498,000 jobs.

3. COVID-19 cases continue to surge across the country, with over 4,000 deaths reported in a single day. Hospitals are facing critical shortages of staff and supplies, as the virus spreads rapidly. Health experts are urging the public to follow safety guidelines to curb the spread of the virus.

4. The U.S. government approved a second COVID-19 vaccine for emergency use, developed by Moderna. The vaccine has shown to be highly effective in clinical trials, with an efficacy rate of 94.1%. Distribution of the vaccine is expected to begin immediately to help combat the ongoing pandemic.

Read more at Nasdaq.: These 4 Billionaires All Have 1 Genius AI Stock in Common, and It’s Set to Skyrocket in 2026 (Hint: It’s Not Nvidia)